Renovaro Inc. (RENB)
- Previous Close
1.7000 - Open
1.7900 - Bid 1.5000 x 100
- Ask 1.5800 x 100
- Day's Range
1.5000 - 2.1000 - 52 Week Range
0.3930 - 5.2500 - Volume
1,042,378 - Avg. Volume
324,279 - Market Cap (intraday)
219.812M - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7000 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
renovarobio.comRecent News: RENB
Performance Overview: RENB
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RENB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RENB
Valuation Measures
Market Cap
219.81M
Enterprise Value
226.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.04
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.16%
Return on Equity (ttm)
-74.63%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-41.23M
Diluted EPS (ttm)
-0.7000
Balance Sheet and Cash Flow
Total Cash (mrq)
243.98k
Total Debt/Equity (mrq)
18.49%
Levered Free Cash Flow (ttm)
-5.01M